Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.57 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22461412 | 0.86 | KDM4E (0.67) | LMNAKDM4EL3MBTL1PLA2G1BPOLB | |
| SCHEMBL1849603 | 0.85 | LMNA (0.77) | LMNAKDM4EL3MBTL1PLA2G1BPOLB | |
| SCHEMBL2289990 | 0.85 | LMNA (0.77) | LMNAKDM4EL3MBTL1PLA2G1BPOLB | |
| SCHEMBL7278068 | 0.85 | LMNA (0.77) | LMNAKDM4EL3MBTL1PLA2G1BPOLB | |
| SCHEMBL4342037 | 0.82 | LMNA (0.53) | LMNAKDM4EL3MBTL1PLA2G1BPOLB | |
| SCHEMBL17519901 | 0.81 | LMNA (0.71) | LMNAKDM4EL3MBTL1PLA2G1BPOLB | |
| SCHEMBL4351380 | 0.81 | LMNA (0.71) | LMNAKDM4EL3MBTL1PLA2G1BPOLB | |
| SCHEMBL6715245 | 0.80 | KDM4E (0.60) | LMNAKDM4EL3MBTL1PLA2G1BATG4B | |
| SCHEMBL8497858 | 0.79 | KDM4E (0.67) | KDM4EPOLBMEN1KMT2AGAA | |
| SCHEMBL2299217 | 0.79 | BCHE (0.64) | LMNABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | LMNA 4716/4885KDM4E 3351/4885L3MBTL1 4845/4885 |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | LMNA 4716/4885KDM4E 3351/4885L3MBTL1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.